 | |
| Type | Public |
|---|---|
| Nasdaq: STIM Russell 2000 Index component | |
| Founded | 2003 |
| Headquarters | Malvern, PA, United States |
Key people | Dan Reuvers (President and CEO)12 Stephen Furlong (CFO)1
Andrew Macan |
Number of employees | 167 As of March 31, 20184 |
| Website | neurostar |
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,4 that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."5
They manufacture a transcranial magnetic stimulation device, NeuroStar.6 The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.
References
References
- "Neuronetics, Inc. Appoints Dan Reuvers as President and CEO".
- "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
- "NeuroStar Executive Team". Neuronetics.
- "Neuronetics, Inc. (stim) IPO". NASDAQ.com.
- Horvath, J. C.; Mathews, J.; Demitrack, M. A.; Pascual-Leone, A. (July 12, 2010). "The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression". Journal of Visualized Experiments (45): 2345. doi:10.3791/2345. PMC 3159591. PMID 21189465.
- "Hello Health: How transcranial magnetic stimulation treats major depressive disorder". November 11, 2020.